EFSD and Sanofi have established a new programme called the EFSD/Sanofi European Pilot Research Grants for Innovative Measurement of Diabetes Outcomes to encourage new projects aimed at advancing current knowledge in this field.
To achieve the goals and objectives of this Programme, EFSD and Sanofi invite applications by issuing this "Request for Applications" (RFA), which indicates joint funding as well as areas of research emphasis.
These EFSD/Sanofi European Pilot Research Grants are intended to help develop innovative means to document and validate novel parameters indicative of long-term benefits for patients with diabetes.
In spite of the growing evidence of the complexity and multifaceted aspects of diabetes, the management of the disease still remains anchored on the lowering of HbA1c. Long term HbA1c lowering has been proven effective at reducing the risk for late complications in randomised clinical trials. Despite the large body of evidence on the value of HbA1c lowering in these studies, achieving target HbA1c is often unmet in the clinical practice of medicine. The life-long duration of the disease, the economic, social, psychological, and physiological burden and limited appreciation of individual needs are likely important interfering factors that contribute to the complexity of the task. Because of such complexity, HbA1c might not be the only “metric” of relevance to assess the possibility for a treatment strategy to provide long term benefit and improved quality of life.
We are now seeking pilot proposals for innovative definition and measurement of outcomes in diabetes. Proposals may include, but need not be limited to, the validation of behavioural, biological, and disease management metrics to complement HbA1c in defining the quality of the long term management of diabetes.
The deadline for receipt of research grant applications for funding is 15 March 2018.
More information in the next link: EFSD and Sanofi European Pilot Research Grants
